Aliment Pharmacol Ther. 2007 Oct 6; [Epub ahead of print]
Clinical trial: multispecies probiotic supplementation alleviates the symptoms of IBS and stabilises intestinal microbiota.
Kajander K, Myllyluoma E, Rajilić-Stojanović M, Kyrönpalo S S, Rasmussen M, Järvenpää S S, Zoetendal EG, de Vos WM, Vapaatalo H, Korpela R. Institute of Biomedicine, Pharmacology, University of Helsinki, Helsinki, Finland, and Valio Ltd, Research Centre, Helsinki, Finland.
Background: Irritable bowel syndrome (IBS) is the most common diagnosis in gastroenterology. Trials suggest certain probiotics to be beneficial. Aim: To investigate the effects of multispecies probiotic supplementation (L. rhamnosus GG, L. rhamnosus Lc705, P. freudenreichii subsp. shermanii JS and B. animalis subsp. lactis Bb12) on abdominal symptoms, quality of life, intestinal microbiota, and inflammatory markers in IBS.
Methods: Eighty-six IBS patients (Rome II criteria) participated in this randomised, placebo-controlled 5-month intervention. Patients were randomised to receive daily either multispecies probiotic supplementation or placebo. IBS symptoms, quality of life, microarray-based intestinal microbiota stability (n=20), serum cytokines and sensitive-CRP were monitored.
Results: The composite IBS score had at five months decreased 14 points (95% CI: -19 to -9) from baseline with the multispecies probiotic versus 3 points (95% CI: -8 to 1) with placebo (p=0.0083). Especially distension and abdominal pain were affected. A stabilisation of the microbiota was observed, as the microbiota similarity index increased with the probiotic supplementation (1.87 +/- 3.13), while it decreased with placebo (-2.93 +/- 1.68). No differences were seen in CRP.
Conclusions: This multispecies probiotic seems to be an effective and safe option to alleviate symptoms of IBS, and to stabilise the intestinal microbiota.
PMID: 17919270 [PubMed - as supplied by publisher]